Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 11:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 315 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vehicle alone Clear all
Terminated Phase 2 Interventional

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

NCT03578029
View directory record Official record
Conditions
Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
Interventions
RGN-137, Placebo
Drug
Lead sponsor
Lenus Therapeutics, LLC
Industry
Eligibility
4 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Evanston, Illinois • Brooklyn, New York • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 12, 2026, 11:09 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

NCT04829344
View directory record Official record
Conditions
Anesthesia, Local
Interventions
AG-920, Placebo
Drug
Lead sponsor
American Genomics, LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 12, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

NCT03638258
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Roflumilast Cream 0.3%, Roflumilast Cream 0.15%, Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
20
States / cities
Beverly Hills, California • Northridge, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 12, 2026, 11:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers

NCT03565861
View directory record Official record
Conditions
Safety Issues
Interventions
Placebo, NP10679
Drug
Lead sponsor
Neurop Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Sep 12, 2026, 11:09 PM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate Effects of an Oral Rinse on Plaque and Gingivitis

NCT03421145
View directory record Official record
Conditions
Plaque
Interventions
3M™ Oral Rinse, Vehicle Control Oral Rinse, PerioShield™ Oral Health Rinse, Water
Device · Other
Lead sponsor
Solventum US LLC
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 12, 2026, 11:09 PM EDT
Completed Phase 2Phase 3 Interventional Results available

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

NCT03292809
View directory record Official record
Conditions
Dry Eye Disease
Interventions
CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Newport Beach, California • Torrance, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 12, 2026, 11:09 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness

NCT01959230
View directory record Official record
Conditions
Hyperemia
Interventions
Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 12, 2026, 11:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Health Literacy and Obesogenic Behaviors

NCT04252677
View directory record Official record
Conditions
Obesity, Adolescent, Health Behavior, Health Knowledge, Attitudes, Practice, Diet, Healthy, Exercise, Health Literacy
Interventions
Obesity Prevention, Health Literacy
Behavioral
Lead sponsor
City University of New York, School of Public Health
Other
Eligibility
13 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 12, 2026, 11:09 PM EDT
Active, not recruiting Phase 1 Interventional

E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults

NCT04057833
View directory record Official record
Conditions
Rotator Cuff Tears, Muscle Atrophy or Weakness, Tendon Rupture - Shoulder, Safety Issues
Interventions
E-CEL UVEC
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 12, 2026, 11:09 PM EDT
Completed Phase 1 Interventional Results available

T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies

NCT02659943
View directory record Official record
Conditions
Lymphoma, B-Cell, Lymphoma, Non-hodgkins
Interventions
Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 73 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Sep 12, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oxytocin as Adjunctive Treatment of Schizophrenia

NCT01568528
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo, Control
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 12, 2026, 11:09 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM

NCT02766699
View directory record Official record
Conditions
Glioblastoma, Astrocytoma, Grade IV
Interventions
EGFR(V)-EDV-Dox
Drug
Lead sponsor
Engeneic Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 12, 2026, 11:09 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

NCT05966493
View directory record Official record
Conditions
Persistent Corneal Epithelial Defect
Interventions
lufepirsen high dose, Vehicle, lufepirsen low dose
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
2 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
21
States / cities
Dothan, Alabama • Petaluma, California • Torrance, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Sep 12, 2026, 11:09 PM EDT
Suspended Phase 1Phase 2 Interventional

Propranolol Treatment for Postoperative Chylothorax

NCT06833320
View directory record Official record
Conditions
Postoperative Chylothorax, Congenital Heart Disease, Open Heart Surgery, Chylothorax
Interventions
Propranolol Hydrochloride, Placebo
Drug
Lead sponsor
June Wu
Other
Eligibility
7 Days to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 12, 2026, 11:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis

NCT03392168
View directory record Official record
Conditions
Psoriasis
Interventions
ARQ-151 cream 0.5%, ARQ-151 cream 0.15%, ARQ-151 vehicle cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Sep 12, 2026, 11:09 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Cantharidin in Molluscum Contagiosum

NCT00667225
View directory record Official record
Conditions
Molluscum Contagiosum, Skin Disease
Interventions
cantharidin's vehicle, Cantharidin 0.7%
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
5 Years to 10 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2011 · Synced Sep 12, 2026, 11:09 PM EDT
Completed Phase 4 Interventional

Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery

NCT03900026
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery, Atherosclerosis, Vein Occlusion
Interventions
Evolocumab, Placebo
Drug · Other
Lead sponsor
Unity Health Toronto
Other
Eligibility
18 Years and older
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
5
States / cities
San Francisco, California • Jacksonville, Florida • Portland, Maine + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 12, 2026, 11:09 PM EDT
Completed Phase 3 Interventional Results available

Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis

NCT02025725
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
Metoclopramide Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
Evoke Pharma
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2020 · Synced Sep 12, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of the Safety and Efficacy of Topical Roflumilast Cream in the Treatment of Facial Papulopustular Rosacea

NCT05278624
View directory record Official record
Conditions
Rosacea
Interventions
Roflumilast Cream
Drug
Lead sponsor
Dermatology Consulting Services, PLLC
Network
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 12, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)

NCT01475955
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Broad Area ALA 1-hour incubation, Broad Area ALA 2 hour incubation, broad area ALA 3-hour incubation, Spot ALA 2 hour incubation, Vehicle PDT, Blue Light Treatment
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 12, 2026, 11:09 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails

NCT01208129
View directory record Official record
Conditions
Onychomycosis
Interventions
NAB001, Placebo control
Drug
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Tucson, Arizona • Phoenix, Arkansas • Rogers, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Sep 12, 2026, 11:09 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

NCT07482787
View directory record Official record
Conditions
Epidermolysis Bullosa (EB)
Interventions
SD-101 Dermal Cream (6%), Vehicle (SD-101 0%)
Drug
Lead sponsor
Paradigm Therapeutics
Industry
Eligibility
28 Days to 12 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Rancho Santa Margarita, California • Redwood City, California • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 12, 2026, 11:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers

NCT03502434
View directory record Official record
Conditions
Tendinopathy
Interventions
SM04755, Vehicle, White Petrolatum, Sodium lauryl sulfate
Drug · Other
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 12, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne

NCT00706433
View directory record Official record
Conditions
Acne Vulgaris
Interventions
aminolevulinic acid HCL (ALA), Vehicle (VEH)
Drug · Other
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2011 · Synced Sep 12, 2026, 11:09 PM EDT